Dermata Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Par Value | Capital | Deficit | Equity | |
| Balance at December 31, 2022 | 51,338 | $5 | $51,615,037 | $(45,593,188) | $6,021,854 |
| Issuance of Common Stock and warrants, net of issuance costs | 36,236 | 4 | 5,651,664 | - | 5,651,668 |
| Issuance of Common Stock upon exercise of pre-funded warrants | 125,029 | 12 | 175 | - | 187 |
| Issuance of Common Stock upon exercise of warrants, net of issuance costs | 49,473 | 5 | 1,953,952 | - | 1,953,957 |
| Settlement of fractional shares paid in cash | (78) | (40) | - | (40) | |
| Stock-based compensation | - | - | 522,082 | - | 522,082 |
| Net loss | - | - | - | (7,794,690) | (7,794,690) |
| Balance at December 31, 2023 | 261,998 | $26 | $59,742,870 | $(53,387,878) | $6,355,018 |
| Issuance of abeyance shares | 182,000 | 18 | (18) | - | - |
| Issuance of Common Stock and warrants from May 2024 Warrant Inducement | 249,336 | 25 | 2,311,513 | - | 2,311,538 |
| Settlement of fractional shares paid in cash | (159) | - | (828) | - | (828) |
| Issuance of pre-funded warrants and warrants from September 2024 PIPE | - | - | 3,081,352 | - | 3,081,352 |
| Issuance of Common Stock upon exercise of pre-funded warrants | 1,007,569 | 101 | 908 | - | 1,009 |
| Issuance of Common Stock from ATM sales, net of issuance costs | 550,024 | 55 | 1,442,762 | - | 1,442,817 |
| Issuance of abeyance shares from warrant inducement | 267,000 | 27 | (27) | - | - |
| Stock-based compensation | - | - | 657,649 | - | 657,649 |
| Net loss | - | - | - | (12,287,461) | (12,287,461) |
| Balance at December 31, 2024 | 2,517,768 | $252 | $67,236,181 | $(65,675,339) | $1,561,094 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.